Stocktoria
GSK plc GSK.L
GSK plc (GSK.L) earns a Piotroski F-score of 9/9 (strong financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 3.23% (safety: moderate). FY2025 revenue was $32.7B at a 17.5% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 23 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 9/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | -0.064 |
| Retained earnings / assets | 0.167 |
| EBIT / assets | 0.136 |
| Equity / liabilities | 0.363 |
FAQ
Is GSK.L financially healthy?
GSK plc's Piotroski F-score is 9/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does GSK.L pay a dividend, and is it safe?
Yes. GSK plc pays a dividend yielding about 3.23% with a 44.9% payout ratio, rated “moderate” for safety.
How profitable is GSK.L?
In FY2025, GSK plc had a net margin of 17.5% and a return on equity of 34.9%.
Source: company filings via Yahoo Finance · GB · as of 2025-12-31. Figures in GBp; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.